{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T01:42:54Z","timestamp":1791164574951,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Splash Pharmaceuticals"},{"DOI":"10.13039\/100007558","name":"Rutgers Cancer Institute of New Jersey","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007558","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1136\/ijgc-2021-003316","type":"journal-article","created":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T10:40:30Z","timestamp":1656067230000},"page":"1032-1038","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Phase I trial of daily subcutaneous SPL-108 injections in combination with paclitaxel in patients with platinum resistant CD44+ advanced ovarian epithelial cancer"],"prefix":"10.1016","volume":"32","clinical-trial-number":[{"clinical-trial-number":"nct03078400","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Eugenia","family":"Girda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm","family":"Finlayson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre Buckley","family":"de Meritens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Chekmareiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliza","family":"Leiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihae","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Stephenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana I","family":"Tergas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Vattakalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason D","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antons","family":"Martincuks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Kohut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joycelynne","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5909-1774","authenticated-orcid":false,"given":"Lorna","family":"Rodriguez-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2021-003316_bb0010","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1136\/ijgc-2021-003316_bb0015","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ygyno.2014.02.038","article-title":"\"Platinum resistant\" ovarian cancer: what is it, who to treat and how to measure benefit?","volume":"133","author":"Davis","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2021-003316_bb0020","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2005.10.036","article-title":"Phase II trial of weekly paclitaxel (80 mg\/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study","volume":"101","author":"Gynecologic Oncology Group","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2021-003316_bb0025","first-page":"S15-62","article-title":"Salvage weekly paclitaxel in recurrent ovarian cancer","volume":"24","author":"Abu-Rustum","year":"1997","journal-title":"Semin Oncol"},{"key":"10.1136\/ijgc-2021-003316_bb0030","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0065-230X(08)60101-3","article-title":"CD44: structure, function, and association with the malignant process","volume":"71","author":"Naor","year":"1997","journal-title":"Adv Cancer Res"},{"key":"10.1136\/ijgc-2021-003316_bb0035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2015.00201","article-title":"Interactions between hyaluronan and its receptors (CD44, RHAMM) regulate the activities of inflammation and cancer","volume":"6","author":"Misra","year":"2015","journal-title":"Front Immunol"},{"key":"10.1136\/ijgc-2021-003316_bb0040","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2017.00018","article-title":"CD44: a multifunctional cell surface adhesion receptor is a regulator of progression and metastasis of cancer cells","volume":"5","author":"Senbanjo","year":"2017","journal-title":"Front Cell Dev Biol"},{"key":"10.1136\/ijgc-2021-003316_bb0045","first-page":"867","article-title":"Glycoprotein CD44 expression and its association with survival in breast cancer","volume":"143","author":"Joensuu","year":"1993","journal-title":"Am J Pathol"},{"key":"10.1136\/ijgc-2021-003316_bb0050","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/0140-6736(93)92879-X","article-title":"De-novo expression of CD44 and survival in gastric cancer","volume":"342","author":"Mayer","year":"1993","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2021-003316_bb0055","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/(SICI)1096-9896(1998100)186:2<157::AID-PATH169>3.0.CO;2-M","article-title":"Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up","volume":"186","author":"Lipponen","year":"1998","journal-title":"J Pathol"},{"key":"10.1136\/ijgc-2021-003316_bb0060","first-page":"4427","article-title":"CD44 stimulation induces integrin-mediated adhesion of colon cancer cell lines to endothelial cells by up-regulation of integrins and c-Met and activation of integrins","volume":"59","author":"Fujisaki","year":"1999","journal-title":"Cancer Res"},{"key":"10.1136\/ijgc-2021-003316_bb0065","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1080\/00016480510026971","article-title":"Soluble CD44 standard, CD44 variant 5 and CD44 variant 6 and their relation to staging in head and neck cancer","volume":"125","author":"Kawano","year":"2005","journal-title":"Acta Otolaryngol"},{"key":"10.1136\/ijgc-2021-003316_bb0070","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-11-340","article-title":"Prognostic significance of CD44s expression in resected non-small cell lung cancer","volume":"11","author":"Ko","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1136\/ijgc-2021-003316_bb0075","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1385\/MO:20:3:255","article-title":"The CD44 receptor is a molecular predictor of survival in ovarian cancer","volume":"20","author":"Rodr\u00edguez-Rodr\u00edguez","year":"2003","journal-title":"Med Oncol"},{"key":"10.1136\/ijgc-2021-003316_bb0080","doi-asserted-by":"crossref","first-page":"17635","DOI":"10.1074\/jbc.M800109200","article-title":"Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells","volume":"283","author":"Bourguignon","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1136\/ijgc-2021-003316_bb0085","doi-asserted-by":"crossref","first-page":"26308","DOI":"10.18632\/oncotarget.4763","article-title":"CD44 promotes multi-drug resistance by protecting P-glycoprotein from FBXO21-mediated ubiquitination","volume":"6","author":"Ravindranath","year":"2015","journal-title":"Oncotarget"},{"key":"10.1136\/ijgc-2021-003316_bb0090","doi-asserted-by":"crossref","first-page":"6660","DOI":"10.1158\/0008-5472.CAN-04-3478","article-title":"The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer","volume":"65","author":"Miletti-Gonz\u00e1lez","year":"2005","journal-title":"Cancer Res"},{"key":"10.1136\/ijgc-2021-003316_bb0095","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.1158\/1078-0432.CCR-13-1536","article-title":"Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug","volume":"19","author":"Shah","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2021-003316_bb0100","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1158\/1535-7163.MCT-11-0351","article-title":"A6 peptide activates CD44 adhesive activity, induces FAK and MEK phosphorylation, and inhibits the migration and metastasis of CD44-expressing cells","volume":"10","author":"Piotrowicz","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1136\/ijgc-2021-003316_bb0105","doi-asserted-by":"crossref","first-page":"13125","DOI":"10.1096\/fj.202000380RR","article-title":"The role of CD44 in pathological angiogenesis","volume":"34","author":"Chen","year":"2020","journal-title":"Faseb J"},{"key":"10.1136\/ijgc-2021-003316_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2015.00135","article-title":"Modulation of CD44 activity by A6-peptide","volume":"6","author":"Finlayson","year":"2015","journal-title":"Front Immunol"},{"key":"10.1136\/ijgc-2021-003316_bb0115","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ygyno.2005.05.023","article-title":"\u00c56, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial","volume":"99","author":"Berkenblit","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2021-003316_bb0120","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/bjc.2016.203","article-title":"ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells","volume":"115","author":"Vaidyanathan","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2021-003316_bb0125","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cell.2008.06.006","article-title":"Growth-inhibitory and tumor suppressive functions of p53 depend on its repression of CD44 expression","volume":"134","author":"Godar","year":"2008","journal-title":"Cell"},{"key":"10.1136\/ijgc-2021-003316_bb0130","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24008247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24008247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2021-003316","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T12:39:17Z","timestamp":1753101557000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24008247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S1048891X24008247"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2021-003316","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I trial of daily subcutaneous SPL-108 injections in combination with paclitaxel in patients with platinum resistant CD44+ advanced ovarian epithelial cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2021-003316","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/.","name":"copyright","label":"Copyright"}]}}